<DOC>
	<DOCNO>NCT02497820</DOCNO>
	<brief_summary>A randomised double blind dose non-inferiority trial daily dose 600mg versus 300mg versus 100mg enteric coat aspirin cancer preventive carrier germline pathological mismatch repair gene defect , Lynch Syndrome . Project 3 Cancer Prevention Programme ( CaPP3 ) .</brief_summary>
	<brief_title>Finding Best Dose Aspirin Prevent Lynch Syndrome Cancers</brief_title>
	<detailed_description>Study design : A randomised , double-blind , dose non-inferiority study . Study Intervention : Enteric-coated aspirin 100mg , 300mg 600mg blind dose daily follow daily 100mg open label dose daily . Primary objective : To determine whether cancer preventive property enteric coat aspirin Lynch syndrome dose sensitive compare overall cumulative Lynch syndrome cancer incidence rate 5 year people take 100mg , 300mg 600mg enteric coat aspirin least 2 year . Secondary objective : Compare overall cumulative incidence primary colorectal cancer use Poisson regression allow multiple primary individual patient three treatment group . Compare overall cumulative incidence primary endometrial cancer use Poisson regression allow multiple primary individual patient three treatment group . Compare overall cumulative incidence cancer type , use Poisson regression allow multiple primary individual patient three treatment group . The burden adverse event associate different aspirin dos relatively young healthy population document . Primary outcome : The number new primary mismatch repair deficient cancer ( `` Lynch syndrome cancer '' ) 5 year beyond develop participant remain prescribed treatment minimum 2 year . Number study site : 4 ISRAEL site . 20 site world . Study population/size : 300 patient ISRAEL . UK 1000-1500 patient . Total International 3,000 patient . Study duration : 7 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Colorectal Neoplasms , Hereditary Nonpolyposis</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>1 . Male female patient ≥ 18 year . 2 . Confirmed germline pathological variant one mismatch repair gene ; MSH2 , MLH1 , PMS2 MSH6 3 ' EPCAM deletion associate MSH2 silence carrier constitutional epimutation manifest classic Lynch syndrome phenotype . 3 . Able swallow tablet . 4 . Provision voluntary write informed consent . 1 . Regular use nonsteroidal antiinflammatory agent ( except aspirin* ) prescription and/or longterm basis . Regular define &gt; 3 dos per week . 2 . Regular use aspirin ( &gt; 3 dos per week prescription basis ) replace one randomise arm study follow 100mg dose . 3 . Current methotrexate use weekly dose ≥ 15mg . 4 . Known aspirin intolerance hypersensitivity , include aspirinsensitive asthma . 5 . Existing clinically significant liver impairment . 6 . Existing renal failure . 7 . Confirmed active peptic ulcer disease within previous three month . 8 . Known bleed diathesis concomitant warfarin therapy . 9 . Inability comply study procedures agent . 10 . Women report pregnant actively plan achieve pregnancy within next two year . 11 . Women breastfeed . 12 . Any significant medical illness would interfere study participation . Previous use aspirin medicinal purpose exclude enrolment duration quantity need document detail</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>